KalVista Pharmaceuticals Statistics
Share Statistics
KalVista Pharmaceuticals has 49.42M shares outstanding. The number of shares has increased by 25.05% in one year.
| Shares Outstanding | 49.42M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 2.43% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 34.67M |
| Failed to Deliver (FTD) Shares | 278 |
| FTD / Avg. Volume | 0.07% |
Short Selling Information
The latest short interest is 6.87M, so 14.11% of the outstanding shares have been sold short.
| Short Interest | 6.87M |
| Short % of Shares Out | 14.11% |
| Short % of Float | 21.23% |
| Short Ratio (days to cover) | 24.86 |
Valuation Ratios
The PE ratio is -3.3 and the forward PE ratio is -5.71.
| PE Ratio | -3.3 |
| Forward PE | -5.71 |
| PS Ratio | 0 |
| Forward PS | 62.5 |
| PB Ratio | 2.02 |
| P/FCF Ratio | -4.66 |
| PEG Ratio | n/a |
Enterprise Valuation
KalVista Pharmaceuticals Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 9.9, with a Debt / Equity ratio of 0.
| Current Ratio | 9.9 |
| Quick Ratio | 9.9 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.61% and return on capital (ROIC) is -61.55%.
| Return on Equity (ROE) | -0.61% |
| Return on Assets (ROA) | -0.54% |
| Return on Capital (ROIC) | -61.55% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -844.29K |
| Employee Count | 150 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -8.45M |
| Effective Tax Rate | 0.06 |
Stock Price Statistics
The stock price has increased by -18.63% in the last 52 weeks. The beta is 0.91, so KalVista Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 0.91 |
| 52-Week Price Change | -18.63% |
| 50-Day Moving Average | 10.67 |
| 200-Day Moving Average | 11.81 |
| Relative Strength Index (RSI) | 36.14 |
| Average Volume (20 Days) | 406.17K |
Income Statement
In the last 12 months, KalVista Pharmaceuticals had revenue of $0 and earned -$126.64M in profits. Earnings per share was $-3.44.
| Revenue | 0 |
| Gross Profit | -86.17M |
| Operating Income | -140.44M |
| Net Income | -126.64M |
| EBITDA | -134.28M |
| EBIT | - |
| Earnings Per Share (EPS) | -3.44 |
Balance Sheet
The company has $31.79M in cash and $7.32M in debt, giving a net cash position of $24.47M.
| Cash & Cash Equivalents | 31.79M |
| Total Debt | 7.32M |
| Net Cash | 24.47M |
| Retained Earnings | -469.73M |
| Total Assets | 160.83M |
| Working Capital | 130.10M |
Cash Flow
In the last 12 months, operating cash flow was -$89.23M and capital expenditures -$443.00K, giving a free cash flow of -$89.67M.
| Operating Cash Flow | -89.23M |
| Capital Expenditures | -443.00K |
| Free Cash Flow | -89.67M |
| FCF Per Share | -2.44 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
KALV does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -39.59% |
| FCF Yield | -20.89% |
Analyst Forecast
The average price target for KALV is $28, which is 222.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $28 |
| Price Target Difference | 222.2% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Stock Splits
The last stock split was on Nov 21, 2016. It was a backward split with a ratio of 1:14.
| Last Split Date | Nov 21, 2016 |
| Split Type | backward |
| Split Ratio | 1:14 |
Scores
| Altman Z-Score | 2.39 |
| Piotroski F-Score | 2 |